Education

Undergraduate School

University of Michigan
1991 Ann Arbor MI

Graduate School

MPH Tufts University
1995 Boston MA

Medical School

Tufts University School of Medicine
1995 Boston MA

Residency

Boston Children's Hospital
1999 Boston MA

Fellowship

Boston Children's Hospital
2003 Boston MA

Media

Caregiver Profile

Meet Dr. Sarah de Ferranti

Publications

  1. Unplanned Readmissions in Pediatric Cardiac Disease: Impacts of Social Determinants of Health. Pediatr Cardiol. 2025 May 17. View Abstract
  2. Myocardial Infarction in Kawasaki Disease. J Pediatr. 2025 May 12; 114638. View Abstract
  3. Trajectory of Cardiovascular Health Across Childhood and Adolescence. JAMA Cardiol. 2025 May 01; 10(5):417-426. View Abstract
  4. Implementation strategies for improving the care of familial hypercholesterolaemia from the International Atherosclerosis Society: next steps in implementation science and practice. Am J Prev Cardiol. 2025 Jun; 22:100993. View Abstract
  5. Prenatal and Perinatal Factors of Life's Essential 8 Cardiovascular Health Trajectories. JAMA Netw Open. 2025 Apr 01; 8(4):e257774. View Abstract
  6. Recent updates on the screening, diagnosis, and management of lipids disorders in children and adolescents. Curr Opin Pediatr. 2025 Mar 27. View Abstract
  7. Expert-Level Automated Diagnosis of the Pediatric ECG Using a Deep Neural Network. JACC Clin Electrophysiol. 2025 Mar 01. View Abstract
  8. Correction: Isometric Exercise Does Not Affect the Diameter of the Ascending Aorta in Youth with Bicuspid Aortic Valves. Pediatr Cardiol. 2025 Jan; 46(1):252. View Abstract
  9. Parent and Primary Care Clinician Perceptions About Pediatric Hypertension. JAMA Netw Open. 2024 Dec 02; 7(12):e2451103. View Abstract
  10. Low-Density Lipoprotein Cholesterol Level Distributions Across Different Ages: Implications for Screening Children for Severe and Familial Hypercholesterolemia. Circulation. 2024 Nov 19; 150(21):1741-1744. View Abstract
  11. Trends in Gaps of Care for Patients With Congenital Heart Disease: Implications for Social Determinants of Health and Child Opportunity Index. J Am Heart Assoc. 2024 Oct 15; 13(20):e034796. View Abstract
  12. Society for Cardiovascular Magnetic Resonance 2023 Cases of SCMR case series. J Cardiovasc Magn Reson. 2024 Winter; 26(2):101086. View Abstract
  13. Forecasting the Burden of Cardiovascular Disease and Stroke in the United States Through 2050-Prevalence of Risk Factors and Disease: A Presidential Advisory From the American Heart Association. Circulation. 2024 Jul 23; 150(4):e65-e88. View Abstract
  14. Enhanced Safety and Efficiency of Ambulatory Cardiology Admissions: A Quality Improvement Initiative. Pediatr Qual Saf. 2024 May-Jun; 9(3):e726. View Abstract
  15. Implementation of the International Consortium of Health Outcomes Measurement CHD standard set in patients undergoing pulmonary valve replacement. Cardiol Young. 2024 Aug; 34(8):1787-1792. View Abstract
  16. It is Time to Screen for Homozygous Familial Hypercholesterolemia in the United States. Glob Heart. 2024; 19(1):43. View Abstract
  17. Food Insecurity and Ideal Cardiovascular Health Risk Factors Among US Adolescents. J Am Heart Assoc. 2024 Apr 16; 13(8):e033323. View Abstract
  18. Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: An expert consensus statement from ERKNet and ESPN. Atherosclerosis. 2024 05; 392:117525. View Abstract
  19. Familial Hypercholesterolemia Variant and Cardiovascular Risk in Individuals With Elevated Cholesterol. JAMA Cardiol. 2024 Mar 01; 9(3):263-271. View Abstract
  20. Social Determinants of Health Including Child Opportunity Index Leading to Gaps in Care for Patients With Significant Congenital Heart Disease. J Am Heart Assoc. 2024 Feb 20; 13(4):e028883. View Abstract
  21. Genetic testing for familial hypercholesterolemia. Curr Opin Lipidol. 2024 04 01; 35(2):93-100. View Abstract
  22. Elevation of IL-17 Cytokines Distinguishes Kawasaki Disease From Other Pediatric Inflammatory Disorders. Arthritis Rheumatol. 2024 02; 76(2):285-292. View Abstract
  23. Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolemia: an expert consensus statement from ERKNet and ESPN. medRxiv. 2023 Nov 15. View Abstract
  24. Still "on the Fence" About Universal Childhood Lipid Screening: The USPSTF Reaffirms an I Statement. JAMA. 2023 07 18; 330(3):225-227. View Abstract
  25. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. Nat Rev Cardiol. 2023 12; 20(12):845-869. View Abstract
  26. Association of Severe Hypercholesterolemia and Familial Hypercholesterolemia Genotype With Risk of Coronary Heart Disease. Circulation. 2023 05 16; 147(20):1556-1559. View Abstract
  27. Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry. J Am Heart Assoc. 2023 05 02; 12(9):e029175. View Abstract
  28. MIS-C across three SARS-CoV-2 variants: Changes in COVID-19 testing and clinical characteristics in a cohort of U.S. children. Eur J Pediatr. 2023 Jun; 182(6):2865-2872. View Abstract
  29. Relationship of Left Ventricular Mass to Lean Body Mass in the Obese Pediatric Population. Pediatr Cardiol. 2024 Mar; 45(3):640-647. View Abstract
  30. The association of objectively measured sedentary time with asthma in US youth: A glimpse into the connection between obesity and asthma. Pediatr Pulmonol. 2023 05; 58(5):1582-1591. View Abstract
  31. Using Adult Ambulatory Blood Pressure Thresholds in Youth: Impact of Nocturnal Hypertension. Hypertension. 2023 04; 80(4):e68-e70. View Abstract
  32. Adherence to lipid-lowering therapy and reaching treatment goals in youth seen in a preventive cardiology clinic. Res Social Adm Pharm. 2023 Mar; 19(3):547-549. View Abstract
  33. Cardiovascular Risk Assessment and Management for Pediatricians. Pediatrics. 2022 12 01; 150(6). View Abstract
  34. Clinical response to lifestyle counseling for dyslipidemia and elevated blood pressure in childhood cancer survivors. Pediatr Blood Cancer. 2023 01; 70(1):e30034. View Abstract
  35. Atherosclerotic Cardiovascular Risk as an Emerging Priority in Pediatrics. Pediatrics. 2022 11 01; 150(5). View Abstract
  36. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of postacute sequelae of SARS-CoV-2 infection (PASC) in children and adolescents. PM R. 2022 10; 14(10):1241-1269. View Abstract
  37. Prevalence of High Blood Pressure Among Youth in India and Association With Future Cardiovascular Disease. JAMA Netw Open. 2022 10 03; 5(10):e2239290. View Abstract
  38. Lack of Age-Appropriate Reference Intervals Causing Potentially Missed Alerts in Clinical Reports of Dyslipidemia. J Pediatr. 2023 01; 252:208-212.e3. View Abstract
  39. Dyslipidemia Among Adults With Congenital Heart Disease. JACC Adv. 2022 Oct; 1(4):100081. View Abstract
  40. Isometric Exercise Increases the Diameter of the Ascending Aorta in Youth with Bicuspid Aortic Valves. Pediatr Cardiol. 2022 Dec; 43(8):1688-1694. View Abstract
  41. Disproportionate Negative Career Impact of the COVID-19 Pandemic on Female Pediatric Cardiologists in the Northeast United States. Pediatr Cardiol. 2022 Dec; 43(8):1913-1921. View Abstract
  42. Estimated Yield of Screening for Heterozygous Familial Hypercholesterolemia With and Without Genetic Testing in US Adults. J Am Heart Assoc. 2022 06 07; 11(11):e025192. View Abstract
  43. Follow-up cardiac magnetic resonance in children with vaccine-associated myocarditis. Eur J Pediatr. 2022 Jul; 181(7):2879-2883. View Abstract
  44. SARS-CoV-2 Infection and Associated Cardiovascular Manifestations and Complications in Children and Young Adults: A Scientific Statement From the American Heart Association. Circulation. 2022 05 10; 145(19):e1037-e1052. View Abstract
  45. Insulin Prevents Hypercholesterolemia by Suppressing 12a-Hydroxylated Bile Acids. Circulation. 2022 03 29; 145(13):969-982. View Abstract
  46. Age, Sex, Race/Ethnicity, and Income Patterns in Ideal Cardiovascular Health Among Adolescents and Adults in the U.S. Am J Prev Med. 2022 04; 62(4):586-595. View Abstract
  47. Association Between Cumulative Low-Density Lipoprotein Cholesterol Exposure During Young Adulthood and Middle Age and Risk of Cardiovascular Events. JAMA Cardiol. 2021 12 01; 6(12):1406-1413. View Abstract
  48. Activity During the COVID-19 Pandemic in Children with Cardiac Rhythm Management Devices. Pediatr Cardiol. 2022 Apr; 43(4):784-789. View Abstract
  49. Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children. JAMA Cardiol. 2021 12 01; 6(12):1446-1450. View Abstract
  50. Special Considerations for Healthy Lifestyle Promotion Across the Life Span in Clinical Settings: A Science Advisory From the American Heart Association. Circulation. 2021 12 14; 144(24):e515-e532. View Abstract
  51. Low-Density Lipoprotein Cholesterol Trajectories and Prevalence of High Low-Density Lipoprotein Cholesterol Consistent With Heterozygous Familial Hypercholesterolemia in US Children. JAMA Pediatr. 2021 10 01; 175(10):1071-1074. View Abstract
  52. Perspectives on Identifying and Treating Familial Hypercholesterolemia in Childhood. Clin Chem. 2021 10 01; 67(10):1312-1317. View Abstract
  53. Helping young women go red: Harnessing the power of personal and digital information to prevent heart disease. Patient Educ Couns. 2021 10; 104(10):2571-2576. View Abstract
  54. Detailed Assessment of Left Ventricular Function in Multisystem Inflammatory Syndrome in Children, Using Strain Analysis. CJC Open. 2021 Jul; 3(7):880-887. View Abstract
  55. Socioeconomic and Racial and/or Ethnic Disparities in Multisystem Inflammatory Syndrome. Pediatrics. 2021 05; 147(5). View Abstract
  56. Improving Cardiovascular Health in a Pediatric Preventive Cardiology Practice. J Pediatr. 2021 05; 232:282-286.e1. View Abstract
  57. Multiple Emergency Department Visits for a Diagnosis of Kawasaki Disease: An Examination of Risk Factors and Outcomes. J Pediatr. 2021 05; 232:127-132.e3. View Abstract
  58. Variation in the management of Kawasaki disease in Australia and New Zealand: A survey of paediatricians. J Paediatr Child Health. 2021 May; 57(5):646-652. View Abstract
  59. Cardiovascular health decline in adolescent girls in the NGHS cohort, 1987-1997. Prev Med Rep. 2020 Dec; 20:101276. View Abstract
  60. Review of Cardiac Involvement in Multisystem Inflammatory Syndrome in Children. Circulation. 2021 01 05; 143(1):78-88. View Abstract
  61. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J Clin Invest. 2020 11 02; 130(11):5942-5950. View Abstract
  62. Evolocumab in Children with Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020 10 01; 383(14):1385-1386. View Abstract
  63. Evidence-Based Policy Making for Public Health Interventions in Cardiovascular Diseases: Formally Assessing the Feasibility of Clinical Trials. Circ Cardiovasc Qual Outcomes. 2020 11; 13(11):e006378. View Abstract
  64. Children with Heterozygous Familial Hypercholesterolemia in the United States: Data from the Cascade Screening for Awareness and Detection-FH Registry. J Pediatr. 2021 02; 229:70-77. View Abstract
  65. Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis. Arch Dis Child. 2021 03; 106(3):247-252. View Abstract
  66. Markers of cholesterol synthesis are elevated in adolescents and young adults with type 2 diabetes. Pediatr Diabetes. 2020 11; 21(7):1126-1131. View Abstract
  67. Atrioventricular Block in Children With Multisystem Inflammatory Syndrome. Pediatrics. 2020 11; 146(5). View Abstract
  68. Update on Preventive Cardiology. Pediatr Clin North Am. 2020 10; 67(5):923-944. View Abstract
  69. Medium-Term Complications Associated With Coronary Artery Aneurysms After Kawasaki Disease: A Study From the International Kawasaki Disease Registry. J Am Heart Assoc. 2020 08 04; 9(15):e016440. View Abstract
  70. Young Women's Perceptions of Heart Disease Risk. J Adolesc Health. 2020 11; 67(5):708-713. View Abstract
  71. Low-Molecular-Weight Heparin vs Warfarin for Thromboprophylaxis in Children With Coronary Artery Aneurysms After Kawasaki Disease: A Pragmatic Registry Trial. Can J Cardiol. 2020 10; 36(10):1598-1607. View Abstract
  72. Cardiovascular Risk and Cardiovascular Health Behaviours in the Transition From Childhood to Adulthood. Can J Cardiol. 2020 09; 36(9):1448-1457. View Abstract
  73. Pediatric Lipid Screening and Treatment in Canada: Practices, Attitudes, and Barriers. Can J Cardiol. 2020 09; 36(9):1545-1549. View Abstract
  74. Missed or delayed diagnosis of Kawasaki disease during the 2019 novel coronavirus disease (COVID-19) pandemic. J Pediatr. 2020 Jul; 222:261-262. View Abstract
  75. Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry. Atherosclerosis. 2020 04; 299:24-31. View Abstract
  76. Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action. JAMA Cardiol. 2020 02 01; 5(2):217-229. View Abstract
  77. The American Heart Association 2030 Impact Goal: A Presidential Advisory From the American Heart Association. Circulation. 2020 03 03; 141(9):e120-e138. View Abstract
  78. Anti-thrombosis management of patients with Kawasaki disease: Results from an international survey. Int J Cardiol. 2020 05 15; 307:154-158. View Abstract
  79. The Use of Nonnutritive Sweeteners in Children. Pediatrics. 2019 11; 144(5). View Abstract
  80. Type 1 diabetes is associated with an increase in cholesterol absorption markers but a decrease in cholesterol synthesis markers in a young adult population. J Clin Lipidol. 2019 Nov - Dec; 13(6):940-946. View Abstract
  81. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation. 2019 09 17; 140(12):e673-e691. View Abstract
  82. Wearable Biosensors in Pediatric Cardiovascular Disease. Circulation. 2019 07 30; 140(5):350-352. View Abstract
  83. Associations of Blood Pressure and Cholesterol Levels During Young Adulthood With Later Cardiovascular Events. J Am Coll Cardiol. 2019 07 23; 74(3):330-341. View Abstract
  84. The relationship between payer type and lipid outcomes in response to clinical lifestyle interventions in youth with dyslipidemia. BMC Pediatr. 2019 07 02; 19(1):217. View Abstract
  85. Is Echocardiography Critical in Patients With Kawasaki Disease With a Z-Score < 2 6 Weeks From Onset?-Reply. JAMA Pediatr. 2019 07 01; 173(7):700-701. View Abstract
  86. Impact of Socioeconomic Status on Outcomes of Patients with Kawasaki Disease. J Pediatr. 2019 09; 212:87-92. View Abstract
  87. Variation in the management of Kawasaki disease. Arch Dis Child. 2020 10; 105(10):1004-1006. View Abstract
  88. Risk Model Development and Validation for Prediction of Coronary Artery Aneurysms in Kawasaki Disease in a North American Population. J Am Heart Assoc. 2019 06 04; 8(11):e011319. View Abstract
  89. Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction. J Am Coll Cardiol. 2019 05 21; 73(19):2439-2450. View Abstract
  90. Trends in Levels of Lipids and Apolipoprotein B in US Youths Aged 6 to 19 Years, 1999-2016. JAMA. 2019 05 21; 321(19):1895-1905. View Abstract
  91. Fish, Shellfish, and Children's Health: An Assessment of Benefits, Risks, and Sustainability. Pediatrics. 2019 May 20. View Abstract
  92. Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis. Pediatrics. 2019 06; 143(6). View Abstract
  93. Impact of Treatment Modality on Vascular Function in Coarctation of the Aorta: The LOVE - COARCT Study. J Am Heart Assoc. 2019 04 02; 8(7):e011536. View Abstract
  94. Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association. Circulation. 2019 03 26; 139(13):e603-e634. View Abstract
  95. Will Teens Go Red? Low Cardiovascular Disease Awareness Among Young Women. J Am Heart Assoc. 2019 03 19; 8(6):e011195. View Abstract
  96. Hepatotoxicity of Statins as Determined by Serum Alanine Aminotransferase in a Pediatric Cohort With Dyslipidemia. J Pediatr Gastroenterol Nutr. 2019 02; 68(2):175-181. View Abstract
  97. Association of Initially Normal Coronary Arteries With Normal Findings on Follow-up Echocardiography in Patients With Kawasaki Disease. JAMA Pediatr. 2018 12 01; 172(12):e183310. View Abstract
  98. Association of Maternal Prepregnancy Weight with Offspring Adiposity Throughout Adulthood over 37 Years of Follow-up. Obesity (Silver Spring). 2019 01; 27(1):137-144. View Abstract
  99. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 06 18; 139(25):e1046-e1081. View Abstract
  100. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 06 18; 139(25):e1082-e1143. View Abstract
  101. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 06 25; 73(24):3168-3209. View Abstract
  102. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 06 25; 73(24):e285-e350. View Abstract
  103. Experience participating in the American College of Cardiology Quality NetworkTM: paediatric and adult congenital cardiology collaborative quality improvement. Cardiol Young. 2019 Jan; 29(1):59-66. View Abstract
  104. Rationale and design of Long-term Outcomes and Vascular Evaluation after Successful Coarctation of the Aorta Treatment study. Ann Pediatr Cardiol. 2018 Sep-Dec; 11(3):282-296. View Abstract
  105. Diagnosis, Evaluation, and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2018 09; 142(3). View Abstract
  106. Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2018 08 07; 72(6):662-680. View Abstract
  107. Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care. J Endocr Soc. 2018 Jun 01; 2(6):497-512. View Abstract
  108. Squaring the Curve of Cardiovascular Health From the Beginning of Life. Pediatrics. 2018 04; 141(4). View Abstract
  109. Prevalence and Predictors of Cholesterol Screening, Awareness, and Statin Treatment Among US Adults With Familial Hypercholesterolemia or Other Forms of Severe Dyslipidemia (1999-2014). Circulation. 2018 05 22; 137(21):2218-2230. View Abstract
  110. Obesity, Hypertension, and Dyslipidemia in Childhood Are Key Modifiable Antecedents of Adult Cardiovascular Disease: A Call to Action. Circulation. 2018 03 20; 137(12):1256-1259. View Abstract
  111. Awareness of Cardiovascular Risk Factors in U.S. Young Adults Aged 18-39 Years. Am J Prev Med. 2018 04; 54(4):e67-e77. View Abstract
  112. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018 03 20; 137(12):e67-e492. View Abstract
  113. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017 Sep; 140(3). View Abstract
  114. USPSTF is unable to recommend for or against lipid screening to identify multifactorial dyslipidaemia in childhood: no recommendation is not without consequences. Evid Based Med. 2017 Oct; 22(5):162-163. View Abstract
  115. PCSK9 Is Increased in Youth With Type 1 Diabetes. Diabetes Care. 2017 07; 40(7):e85-e87. View Abstract
  116. Safety and Efficacy of Warfarin Therapy in Kawasaki Disease. J Pediatr. 2017 10; 189:61-65. View Abstract
  117. Statin-Associated Myopathy in a Pediatric Preventive Cardiology Practice. J Pediatr. 2017 06; 185:94-98.e1. View Abstract
  118. Kawasaki disease and immunisation: A systematic review. Vaccine. 2017 03 27; 35(14):1770-1779. View Abstract
  119. Cholesterol Screening and Treatment Practices and Preferences: A Survey of United States Pediatricians. J Pediatr. 2017 06; 185:99-105.e2. View Abstract
  120. Extracellular RNAs Are Associated With Insulin Resistance and Metabolic Phenotypes. Diabetes Care. 2017 Apr; 40(4):546-553. View Abstract
  121. Ideal Cardiovascular Health, Cardiovascular Remodeling, and Heart Failure in Blacks: The Jackson Heart Study. Circ Heart Fail. 2017 Feb; 10(2). View Abstract
  122. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017 03 07; 135(10):e146-e603. View Abstract
  123. Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women. Pediatr Diabetes. 2017 Dec; 18(8):755-760. View Abstract
  124. Calorically restricted diets decrease PCSK9 in overweight adolescents. Nutr Metab Cardiovasc Dis. 2017 Apr; 27(4):342-349. View Abstract
  125. Stakeholders' Perspectives on Stakeholder-engaged Research (SER): Strategies to Operationalize Patient-centered Outcomes Research Principles for SER. Med Care. 2017 Jan; 55(1):19-30. View Abstract
  126. Kawasaki disease and immunisation: Standardised case definition & guidelines for data collection, analysis. Vaccine. 2016 12 12; 34(51):6582-6596. View Abstract
  127. Transitioning from pediatric to adult health care with familial hypercholesterolemia: Listening to young adult and parent voices. J Clin Lipidol. 2017 Jan - Feb; 11(1):147-159. View Abstract
  128. Adolescent Dyslipidemia and Standardized Lifestyle Modification: Benchmarking Real-World Practice. J Am Coll Cardiol. 2016 11 08; 68(19):2122-2123. View Abstract
  129. Nutrition in Children and Adolescents. Med Clin North Am. 2016 Nov; 100(6):1217-1235. View Abstract
  130. Response by de Ferranti et al to Letter Regarding Article, "Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES)". Circulation. 2016 11 01; 134(18):e395-e396. View Abstract
  131. Transitions in Metabolic Risk and Long-Term Cardiovascular Health: Coronary Artery Risk Development in Young Adults (CARDIA) Study. J Am Heart Assoc. 2016 10 13; 5(10). View Abstract
  132. Cardiovascular Consequences of Childhood Secondhand Tobacco Smoke Exposure: Prevailing Evidence, Burden, and Racial and Socioeconomic Disparities: A Scientific Statement From the American Heart Association. Circulation. 2016 10 18; 134(16):e336-e359. View Abstract
  133. Correlates of Achieving Statin Therapy Goals in Children and Adolescents with Dyslipidemia. J Pediatr. 2016 Nov; 178:149-155.e9. View Abstract
  134. Lipid Screening in Children and Adolescents. JAMA. 2016 Aug 09; 316(6):589-91. View Abstract
  135. Young adult and parent stakeholder perspectives on participation in patient-centered comparative effectiveness research. J Comp Eff Res. 2016 08; 5(5):487-97. View Abstract
  136. Census tract based income level and lipid levels in urban pediatric primary care: a retrospective study. BMC Pediatr. 2016 07 08; 16:86. View Abstract
  137. Long-Term Risk of Atherosclerotic Cardiovascular Disease in US Adults With the Familial Hypercholesterolemia Phenotype. Circulation. 2016 Jul 05; 134(1):9-19. View Abstract
  138. The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia. Circulation. 2016 Jul 05; 134(1):61-72. View Abstract
  139. Adolescent Perceptions of Cholesterol Screening Results: "Young Invincibles" or Developing Adults? J Adolesc Health. 2016 08; 59(2):162-70. View Abstract
  140. Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). Circulation. 2016 Mar 15; 133(11):1067-72. View Abstract
  141. Effect of Leptin Replacement on PCSK9 in ob/ob Mice and Female Lipodystrophic Patients. Endocrinology. 2016 Apr; 157(4):1421-9. View Abstract
  142. Executive Summary: Heart Disease and Stroke Statistics--2016 Update: A Report From the American Heart Association. Circulation. 2016 Jan 26; 133(4):447-54. View Abstract
  143. Premature subclinical atherosclerosis in children and young adults with juvenile idiopathic arthritis. A review considering preventive measures. Pediatr Rheumatol Online J. 2016 Jan 06; 14(1):3. View Abstract
  144. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016 Jan 26; 133(4):e38-360. View Abstract
  145. Massachusetts Pediatricians' Views Toward Body Mass Index Screening in Schools: Continued Controversy. Clin Pediatr (Phila). 2016 08; 55(9):844-50. View Abstract
  146. The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. Circulation. 2015 Dec 01; 132(22):2167-92. View Abstract
  147. Effect on Physical Activity of a Randomized Afterschool Intervention for Inner City Children in 3rd to 5th Grade. PLoS One. 2015; 10(10):e0141584. View Abstract
  148. Factors Associated with Clinical Research Recruitment in a Pediatric Academic Medical Center--A Web-Based Survey. PLoS One. 2015; 10(10):e0140768. View Abstract
  149. Coronary Artery Aneurysm Measurement and Z Score Variability in Kawasaki Disease. J Am Soc Echocardiogr. 2016 Feb; 29(2):150-7. View Abstract
  150. Providing food to treat adolescents at risk for cardiovascular disease. Obesity (Silver Spring). 2015 Oct; 23(10):2109-17. View Abstract
  151. Application of Pediatric and Adult Guidelines for Treatment of Lipid Levels Among US Adolescents Transitioning to Young Adulthood. JAMA Pediatr. 2015 Jun; 169(6):569-74. View Abstract
  152. Treatment decision making for adolescents with familial hypercholesterolemia: Role of family history and past experiences. J Clin Lipidol. 2015 Jul-Aug; 9(4):583-93.e1-3. View Abstract
  153. Familial hypercholesterolemia in children and adolescents: A clinical perspective. J Clin Lipidol. 2015 Sep-Oct; 9(5 Suppl):S11-9. View Abstract
  154. Childhood environmental tobacco smoke exposure: a smoking gun for atherosclerosis in adulthood. Circulation. 2015 Apr 07; 131(14):1231-3. View Abstract
  155. Associations of total and abdominal adiposity with risk marker patterns in children at high-risk for cardiovascular disease. BMC Obes. 2015; 2:15. View Abstract
  156. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015 Jan 27; 131(4):e29-322. View Abstract
  157. Rates of cholesterol screening of youth--reply. JAMA. 2014 Oct 01; 312(13):1354. View Abstract
  158. Cardiovascular disease risk factors in youth with diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2014 Oct 21; 130(17):1532-58. View Abstract
  159. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2014 Oct; 37(10):2843-63. View Abstract
  160. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Circulation. 2014 Sep 23; 130(13):1110-30. View Abstract
  161. Temporal trends in pulse pressure and mean arterial pressure during the rise of pediatric obesity in US children. J Am Heart Assoc. 2014 May 08; 3(3):e000725. View Abstract
  162. Cholesterol testing among children and adolescents during health visits. JAMA. 2014 May 07; 311(17):1804-7. View Abstract
  163. Using high-dose omega-3 fatty acid supplements to lower triglyceride levels in 10- to 19-year-olds. Clin Pediatr (Phila). 2014 May; 53(5):428-38. View Abstract
  164. A compound heterozygous mutation in GPD1 causes hepatomegaly, steatohepatitis, and hypertriglyceridemia. Eur J Hum Genet. 2014 Oct; 22(10):1229-32. View Abstract
  165. Observational studies may be more important than randomized clinical trials: weaknesses in US Preventive Services Task Force recommendation on blood pressure screening in youth. Hypertension. 2014 Apr; 63(4):638-40. View Abstract
  166. Leveraging electronic health records to notify pediatric patients of a drug recall. JAMA Pediatr. 2013 Dec; 167(12):1170-1. View Abstract
  167. Childhood obesity: today and tomorrow's health challenge. J Obes. 2013; 2013:208392. View Abstract
  168. Myocardial tissue remodeling in adolescent obesity. J Am Heart Assoc. 2013 Aug 20; 2(4):e000279. View Abstract
  169. Vascular health in Kawasaki disease. J Am Coll Cardiol. 2013 Sep 17; 62(12):1114-1121. View Abstract
  170. Promotion of physical activity for children and adults with congenital heart disease: a scientific statement from the American Heart Association. Circulation. 2013 May 28; 127(21):2147-59. View Abstract
  171. The Changing Demographics of Congenital Heart Disease Hospitalizations in the United States, 1998 Through 2010. JAMA. 2013 Mar 13; 309(10):984-986. View Abstract
  172. NHLBI integrated pediatric guidelines: battle for a future free of cardiovascular disease. Future Cardiol. 2013 Jan; 9(1):13-22. View Abstract
  173. Pediatric metabolic syndrome: from prevention to treatment. Cholesterol. 2012; 2012:374168. View Abstract
  174. Hypertension in children and adolescents: more questions than answers. Arch Pediatr Adolesc Med. 2012 Sep; 166(9):872-4. View Abstract
  175. Declining cholesterol levels in US youths: a reason for optimism. JAMA. 2012 Aug 08; 308(6):621-2. View Abstract
  176. NHLBI Integrated Guidelines on Cardiovascular Disease Risk Reduction: can we clarify the controversy about cholesterol screening and treatment in childhood? Clin Chem. 2012 Dec; 58(12):1626-30. View Abstract
  177. Dynamic evolution of practice guidelines: analysis of deviations from assessment and management plans. Pediatrics. 2012 Jul; 130(1):93-8. View Abstract
  178. Childhood cholesterol disorders: the iceberg base or nondisease? Med Clin North Am. 2012 Jan; 96(1):141-54. View Abstract
  179. Nontraditional risk factors and biomarkers for cardiovascular disease: mechanistic, research, and clinical considerations for youth: a scientific statement from the American Heart Association. Circulation. 2011 Jun 14; 123(23):2749-69. View Abstract
  180. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun; 5(3 Suppl):S1-8. View Abstract
  181. Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun; 5(3 Suppl):S30-7. View Abstract
  182. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 May-Jun; 5(3):133-140. View Abstract
  183. Hypertriglyceridemia in a pediatric referral practice: experience with 300 patients. Clin Pediatr (Phila). 2011 Apr; 50(4):297-307. View Abstract
  184. Cardiovascular risk assessment and cholesterol management in adolescents: getting to the heart of the matter. Curr Opin Pediatr. 2010 Aug; 22(4):398-404. View Abstract
  185. Recovery from metabolic syndrome is both possible and beneficial. Clin Chem. 2010 Jul; 56(7):1053-5. View Abstract
  186. Endothelial pulse amplitude testing: feasibility and reproducibility in adolescents. J Pediatr. 2009 Jun; 154(6):901-5. View Abstract
  187. Storm over statins--the controversy surrounding pharmacologic treatment of children. N Engl J Med. 2008 Sep 25; 359(13):1309-12. View Abstract
  188. The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem. 2008 Jun; 54(6):945-55. View Abstract
  189. Epidemiology of paediatric metabolic syndrome and type 2 diabetes mellitus. Diab Vasc Dis Res. 2007 Dec; 4(4):285-96. View Abstract
  190. Obesity is a common comorbidity in children with congenital and acquired heart disease. Pediatrics. 2007 Nov; 120(5):e1157-64. View Abstract
  191. Nonfasting low-density lipoprotein testing: utility for cholesterol screening in pediatric primary care. Clin Pediatr (Phila). 2007 Jun; 46(5):441-5. View Abstract
  192. C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovasc Pathol. 2007 Jan-Feb; 16(1):14-21. View Abstract
  193. Inflammation and changes in metabolic syndrome abnormalities in US adolescents: findings from the 1988-1994 and 1999-2000 National Health and Nutrition Examination Surveys. Clin Chem. 2006 Jul; 52(7):1325-30. View Abstract
  194. Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation. 2004 Oct 19; 110(16):2494-7. View Abstract
  195. Intraoperative hyperglycemia during infant cardiac surgery is not associated with adverse neurodevelopmental outcomes at 1, 4, and 8 years. Anesthesiology. 2004 Jun; 100(6):1345-52. View Abstract
  196. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. Clin Chim Acta. 2002 Mar; 317(1-2):1-15. View Abstract
  197. Direct measurement of LDL-C in children: performance of two surfactant-based methods in a general pediatric population. Clin Biochem. 2000 Mar; 33(2):89-95. View Abstract
  198. Are amoxycillin and folate inhibitors as effective as other antibiotics for acute sinusitis? A meta-analysis. BMJ. 1998 Sep 05; 317(7159):632-7. View Abstract
  199. Large trials vs meta-analysis of smaller trials: how do their results compare? JAMA. 1996 Oct 23-30; 276(16):1332-8. View Abstract

Contact Sarah deFerranti

Print Profile